CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration.
Adult
Aged
Antigens, Differentiation, T-Lymphocyte
/ metabolism
Breast Neoplasms
/ genetics
Cytoplasm
/ metabolism
Disease-Free Survival
Female
Humans
Immunohistochemistry
Killer Cells, Natural
/ immunology
Membrane Proteins
/ metabolism
Middle Aged
Prognosis
Receptors, Virus
/ genetics
Retrospective Studies
Survival Analysis
Breast cancer
CD155
Innate immunity
NK-TILs
Prognosis
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
15 Aug 2019
15 Aug 2019
Historique:
received:
17
04
2019
revised:
31
05
2019
accepted:
05
06
2019
pubmed:
10
6
2019
medline:
21
9
2019
entrez:
10
6
2019
Statut:
ppublish
Résumé
CD155 is a ligand of the NK activating receptor DNAM-1, it has been described in a variety of human malignancies, but its expression in breast cancer remains unclear and poorly studied. CD155 expression and NK cells infiltration were investigated in 158 patients with breast cancer by immunohistochemistry (IHC). Statistical analyses were performed to evaluate correlations of CD155 expression with clinical-pathological features, prognosis and tumor immunity. Tumor cytoplasmic CD155 (cyt-CD155) was associated with lymphovascular invasion (p = 0.011), and membranous CD155 (m-CD155) was strongly correlated with the presence of Tumor Infiltrating natural killer cells (NK-TILs) (p = 0.0003). Survival analysis demonstrated that patients with high cyt-CD155 had a significantly worse overall survival (p < 0.001) and death free survival (p = 0.014) than those with low expression, while high levels of m-CD155 correlated with a better prognosis (p = 0.037). Furthermore, we found that patients with m-CD155 Altogether, our results revealed that cyt-CD155 was associated with invasiveness and poorer prognosis, but the concomitant presence of m-CD155 and NK-TILs had an opposite prognostic relevance in breast cancer. These results raised the importance of CD155 IHC analysis to elucidate biomarker localization, leading to better understand and design therapeutic molecule targeting CD155 in breast tumors.
Identifiants
pubmed: 31176775
pii: S0024-3205(19)30463-1
doi: 10.1016/j.lfs.2019.116543
pii:
doi:
Substances chimiques
Antigens, Differentiation, T-Lymphocyte
0
CD226 antigen
0
Membrane Proteins
0
Receptors, Virus
0
poliovirus receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
116543Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.